Family History of Pulmonary Fibrosis Predicts Worse Survival in Patients With Interstitial Lung Disease.
Claire C Cutting, Willis S Bowman, Nam Dao...
https://pubmed.ncbi.nlm.nih.gov/33484728/Actively Recruiting
Led by Royal College of Surgeons, Ireland · Updated on 2024-11-22
300
Participants Needed
1
Research Sites
91 weeks
Total Duration
Researchers are studying pulmonary fibrosis, a group of lung diseases that cause lung scarring and breathing difficulties. This study focuses on how genes and environmental factors contribute to pulmonary fibrosis development and progression, especially in people with idiopathic pulmonary fibrosis IPF, familial pulmonary fibrosis FPF, and connective tissue disease-related interstitial lung disease CTD-ILD. The goal is to better understand disease behavior and improve early identification of progressive cases. Participants are grouped into three categories those with familial pulmonary fibrosis, those with IPF without family history, and those with CTD-ILD. The study follows 300 patients for one year, monitoring lung function and disease progression using several tests, including spirometry, six-minute walk tests, high-resolution CT scans analyzed by AI, genetic testing, and quality of life questionnaires. Participants also use a home monitoring app to track lung function twice a week. During the study, patients undergo assessments at baseline, six months, and twelve months, including lung function tests, blood tests, exercise capacity evaluations, and questionnaire surveys. Researchers will analyze genetic variants, disease progression, and radiological patterns. The study aims to identify early signs of worsening disease and improve personalized diagnosis and care. Safety and overall health are monitored throughout the one-year follow-up.
CONDITIONS
Precision Diagnosis and Care for Families With Pulmonary Fibrosis in Ireland
K
Killian Hurley
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Royal College of Surgeons, Ireland
Lead Sponsor
patientMpower Ltd.
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Baseline to 1 year
Participants undergo diagnostic assessments including genetic testing, serology, spirometry, six minute walk test, and CT thorax scans.
Visits at 0, 6, and 12 months
Duration - Up to 12 months
Participants are monitored using home-based digital spirometry and pulse-oximetry via the PatientMPower Home Monitoring App with real-time feedback.
Twice weekly at-home monitoring
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Claire C Cutting, Willis S Bowman, Nam Dao...
https://pubmed.ncbi.nlm.nih.gov/33484728/David Zhang, Chad A Newton
https://pubmed.ncbi.nlm.nih.gov/34186035/Anna L Peljto, Rachel Z Blumhagen, Avram D Walts...
https://pubmed.ncbi.nlm.nih.gov/36602845/V Navaratnam, K M Fleming, J West...
https://pubmed.ncbi.nlm.nih.gov/21525528/Anthony J Tyndall, Bettina Bannert, Madelon Vonk...
https://pubmed.ncbi.nlm.nih.gov/20551155/Mei Yang, Yanqing Wu, Xuemei Liu...
https://pubmed.ncbi.nlm.nih.gov/37315742/Oliver Distler, Kristin B Highland, Martina Gahlemann...
https://pubmed.ncbi.nlm.nih.gov/31112379/Raphael Borie, Caroline Kannengiesser, Sandrine Hirschi...
https://pubmed.ncbi.nlm.nih.gov/25612863/Royal College of Surgeons, Ireland
Lead Sponsor
patientMpower Ltd.
Collaborating Sponsor